Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

62.75
+0.19000.30%
Volume:20.74K
Turnover:1.30M
Market Cap:5.24B
PE:-102.87
High:62.75
Open:62.52
Low:62.20
Close:62.56
52wk High:90.87
52wk Low:61.23
Shares:83.46M
Float Shares:73.65M
Volume Ratio:0.67
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-31.67
PE(LYR):8.07

Loading ...

PTC Therapeutics Price Target Cut to $75.00/Share from $85.00 by RBC Capital

Dow Jones
·
Yesterday

PTC Therapeutics price target lowered to $75 from $85 at RBC Capital

TIPRANKS
·
Yesterday

RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating

MT Newswires Live
·
Yesterday

PTC Therapeutics EVP, CLO Mark Elliott Boulding Reports $132,809 Common Stock Sale

Reuters
·
Yesterday

PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says

MT Newswires Live
·
Oct 07

PTC Therapeutics (PTCT) Gets a Buy from Barclays

TIPRANKS
·
Oct 07

PTC Therapeutics Director Glenn Steele Jr Reports Sale of 12,000 Common Shares Worth $781,920

Reuters
·
Oct 03

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 26

PTC Therapeutics is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22

PTC Therapeutics Acquires Fabry Gene Therapy Candidate ST-920

TIPRANKS
·
Sep 22

PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease

MT Newswires Live
·
Sep 22

PTC Completes Acquisition of St-920 Fabry Disease Gene Therapy

THOMSON REUTERS
·
Sep 22

PTC Therapeutics, - Expects St-920 Bla Submission to FDA Completed in Q4 2026

THOMSON REUTERS
·
Sep 22

Sangamo Exits ST-920 Gene Therapy Assets in Chapter 11 Sale to PTC for USD 111 Million

Reuters
·
Sep 22

PTC Therapeutics Director Michael Schmertzler Disposes of Common Shares Worth $1.34 Million

Reuters
·
Sep 19

PTC Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
Sep 14

PTC Therapeutics, Inc. : Leerink Partners Assumes Coverage with Outperform vs Market Perform Rating; Target Price $98 vs $70

THOMSON REUTERS
·
Sep 14

PTC Therapeutics Director Michael Schmertzler Disposes of USD 1.35 Million in Common Shares

Reuters
·
Sep 12

Wells Fargo Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

TIPRANKS
·
Sep 02

PTC Therapeutics (PTCT) Stock May Trade Above Fair Value Despite An 81% Run

Simply Wall St.
·
Sep 02